Clinical trials: Poor Graft Function

Poor Graft Function

Study of Efficacy and Safety of Eltrombopag in Patients With Poor Graft Function

• Terminated
• Age: 18 to 100 years
• Phase 2
• Results posted

The purpose of this study was to evaluate the efficacy of eltrombopag for poor graft function (PGF) on overall hematologic response (partial and complete), as determined by platelet, hemoglobin and neutrophil counts by 16 weeks…

Trial name

ELTION (NCT03718533)

Testing

Eltrombopag

Where

7 sites in Spain

Volunteers

10 people

Sponsor

Novartis Pharmaceuticals